interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibMonitor Closely (2)fedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2C19 substrates as necessary. fedratinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenbufenMonitor Closely (1)clomipramine, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fenfluramineMonitor Closely (3)fenfluramine, clomipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. clomipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. clomipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)clomipramine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fenoprofenMonitor Closely (1)clomipramine, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fesoterodineMonitor Closely (1)fesoterodine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.fexinidazoleMonitor Closely (2)fexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. fexinidazole will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fexinidazole and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.fingolimodMonitor Closely (1)fingolimod and clomipramine both increase QTc interval. Use Caution/Monitor.flavoxateMonitor Closely (1)flavoxate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainideMonitor Closely (1)clomipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluconazoleSerious - Use Alternative (2)clomipramine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug. fluconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.fludrocortisoneMinor (1)fludrocortisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.fluoxetineMonitor Closely (1)clomipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (2)fluoxetine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. fluoxetine will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluphenazineMonitor Closely (1)fluphenazine and clomipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)fluphenazine and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)clomipramine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. clomipramine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.flurazepamMonitor Closely (1)flurazepam and clomipramine both increase sedation. Use Caution/Monitor.flurbiprofenMonitor Closely (1)clomipramine, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.fluvoxamineMonitor Closely (1)fluvoxamine and clomipramine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)fluvoxamine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.formoterolMonitor Closely (1)clomipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (2)clomipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug. clomipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.fosamprenavirMonitor Closely (1)fosamprenavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)fosamprenavir increases levels of clomipramine by decreasing metabolism. Avoid or Use Alternate Drug.fosaprepitantMonitor Closely (1)fosaprepitant will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.foscarnetMonitor Closely (1)clomipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.fosphenytoinMonitor Closely (1)fosphenytoin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.frovatriptanMonitor Closely (1)frovatriptan and clomipramine both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentinMonitor Closely (1)gabapentin, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilMonitor Closely (1)gabapentin enacarbil, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantamineMonitor Closely (1)galantamine increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.ganaxoloneMonitor Closely (1)clomipramine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacinMonitor Closely (1)gemifloxacin and clomipramine both increase QTc interval. Use Caution/Monitor.gilteritinibMonitor Closely (1)gilteritinib and clomipramine both increase QTc interval. Use Caution/Monitor.givosiranSerious - Use Alternative (2)givosiran will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP1A2 substrates with givosiran. If unavoidable, decrease the CYP1A2 substrate dosage in accordance with approved product labeling. givosiran will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glimepirideMinor (1)clomipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizideMinor (1)clomipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glofitamabMonitor Closely (1)glofitamab, clomipramine. affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Glofitamab causes release of cytokines that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. For certain CYP substrates, minimal changes in their concentration may lead to serious adverse reactions. If needed, modify therapy as recommended in the substrate's prescribing information. .glyburideMinor (1)clomipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.glycopyrrolateMonitor Closely (2)glycopyrrolate and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. clomipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.glycopyrrolate inhaledMonitor Closely (2)glycopyrrolate inhaled and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. clomipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.glycopyrronium tosylate topicalMonitor Closely (1)glycopyrronium tosylate topical, clomipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetronSerious - Use Alternative (2)granisetron, clomipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. granisetron and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.grapefruitMonitor Closely (1)grapefruit will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.griseofulvinMinor (1)griseofulvin will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.guanfacineSerious - Use Alternative (1)clomipramine decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.haloperidolMonitor Closely (1)haloperidol and clomipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)clomipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. haloperidol will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.henbaneMonitor Closely (1)henbane and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropineMonitor Closely (1)homatropine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and clomipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodoneMonitor Closely (1)hydrocodone, clomipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydrocortisoneMinor (1)hydrocortisone will decrease the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.hydromorphoneMonitor Closely (1)hydromorphone and clomipramine both increase sedation. Use Caution/Monitor.hydroxychloroquine sulfateSerious - Use Alternative (1)hydroxychloroquine sulfate and clomipramine both increase QTc interval. Avoid or Use Alternate Drug.hydroxyprogesterone caproate (DSC)Minor (1)hydroxyprogesterone caproate (DSC), clomipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.hydroxyzineMonitor Closely (2)hydroxyzine and clomipramine both increase sedation. Use Caution/Monitor. hydroxyzine and clomipramine both increase QTc interval. Use Caution/Monitor.hyoscyamineMonitor Closely (1)hyoscyamine and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ibuprofenMonitor Closely (1)clomipramine, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.ibuprofen IVMonitor Closely (1)clomipramine, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.ibutilideContraindicated (1)clomipramine and ibutilide both increase QTc interval. Contraindicated.iloperidoneMonitor Closely (2)clomipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely. iloperidone and clomipramine both increase sedation. Use Caution/Monitor.imatinibMonitor Closely (1)imatinib will increase the level or effect of clomipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.imipramineMonitor Closely (2)clomipramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. clomipramine and imipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)clomipramine and imipramine both increase QTc interval. Avoid or Use Alternate Drug. clomipramine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.indacaterol, inhaledMonitor Closely (1)indacaterol, inhaled, clomipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.indapamideContraindicated (1)clomipramine and indapamide both increase QTc interval. Contraindicated.indinavirMonitor Closely (1)indinavir will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.indomethacinMonitor Closely (1)clomipramine, indomethacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.insulin aspartMinor (1)clomipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirMinor (1)clomipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glargineMinor (1)clomipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisineMinor (1)clomipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisproMinor (1)clomipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHMinor (1)clomipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humanMinor (1)clomipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.iobenguane I 123Contraindicated (1)clomipramine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.iobenguane I 131Serious - Use Alternative (1)clomipramine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.ipratropiumMonitor Closely (1)ipratropium and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isocarboxazidContraindicated (1)isocarboxazid and clomipramine both increase serotonin levels. Contraindicated.isofluraneMonitor Closely (1)isoflurane and clomipramine both increase QTc interval. Use Caution/Monitor.isoniazidMonitor Closely (2)isoniazid will increase the level or effect of clomipramine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. clomipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.Minor (1)isoniazid will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.isoproterenolMonitor Closely (1)clomipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)clomipramine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)isoproterenol, clomipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.itraconazoleMonitor Closely (1)itraconazole and clomipramine both increase QTc interval. Use Caution/Monitor.Minor (1)itraconazole will increase the level or effect of clomipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ivosidenibSerious - Use Alternative (1)ivosidenib and clomipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc